AXGN Quote, Financials, Valuation and Earnings

IRIDEX has a net margin of -7.9% compared to Axogen's net margin of -14.17%. Axogen's return on equity of -7.2% beat IRIDEX's return on equity of -218.69%.

Axogen has a consensus price target of $24.29, signalling upside risk potential of 105.46%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 86.92%. Given that Axogen has higher upside potential than IRIDEX, analysts believe Axogen is more attractive than IRIDEX.

Axogen has a beta of 1.040, which suggesting that the stock is 4.035% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than IRIDEX quarterly revenues of $11.9M. Axogen's net income of -$3.8M is lower than IRIDEX's net income of -$1.7M. Notably, Axogen's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.72x versus 0.36x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical has a net margin of -7.9% compared to Axogen's net margin of --. Axogen's return on equity of -7.2% beat Modular Medical's return on equity of --.

Axogen has a consensus price target of $24.29, signalling upside risk potential of 105.46%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 1034.59%. Given that Modular Medical has higher upside potential than Axogen, analysts believe Modular Medical is more attractive than Axogen.

Axogen has a beta of 1.040, which suggesting that the stock is 4.035% more volatile than S&P 500. In comparison Modular Medical has a beta of -4.943, suggesting its less volatile than the S&P 500 by 594.256%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Modular Medical quarterly revenues of --. Axogen's net income of -$3.8M is higher than Modular Medical's net income of -$4.9M. Notably, Axogen's price-to-earnings ratio is -- while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.72x versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -7.9% compared to Axogen's net margin of -35.24%. Axogen's return on equity of -7.2% beat Myomo's return on equity of -38.11%.

Axogen has a consensus price target of $24.29, signalling upside risk potential of 105.46%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 346.15%. Given that Myomo has higher upside potential than Axogen, analysts believe Myomo is more attractive than Axogen.

Axogen has a beta of 1.040, which suggesting that the stock is 4.035% more volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Myomo quarterly revenues of $9.8M. Axogen's net income of -$3.8M is lower than Myomo's net income of -$3.5M. Notably, Axogen's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.72x versus 1.97x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -7.9% compared to Axogen's net margin of -77.93%. Axogen's return on equity of -7.2% beat Stereotaxis's return on equity of -174.6%.

Axogen has a consensus price target of $24.29, signalling upside risk potential of 105.46%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 88.29%. Given that Axogen has higher upside potential than Stereotaxis, analysts believe Axogen is more attractive than Stereotaxis.

Axogen has a beta of 1.040, which suggesting that the stock is 4.035% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.964%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Stereotaxis quarterly revenues of $7.5M. Axogen's net income of -$3.8M is higher than Stereotaxis's net income of -$5.8M. Notably, Axogen's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.72x versus 7.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.